Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reforming the 340B Drug Pricing Program

Reforming the 340B Drug Pricing Program Letters a background review for an American College of Physicians Clinical Practice cessful. However, most interventions have focused on Guideline. Ann Intern Med. 2011;155(9):602-615. increasing overall rates of prophylaxis rather than overall appropriateness. Although overall rates have improved, the 6. Rothberg MB. Venous thromboembolism prophylaxis for medical patients: who needs it? JAMA Intern Med. 2014;174(10):1585-1586. unintended consequence may be excess administration of VTE prophylaxis among low-risk patients. The major drawback to pharmacologic overprophylaxis is HEALTH CARE POLICY AND LAW major bleeding. Patient discomfort, potential risk of falls and Diversity of Participants in the 340B Drug Pricing impaired mobility with mechanical prophylaxis, medication Program for US Hospitals cost, and risk for heparin-induced thrombocytopenia are ad- The 340B program was initiated in 1992 by the US Congress ditional concerns. to allow participating hospitals to generate additional rev- Limitations of this study include its observational design enue by purchasing certain drugs used for outpatient care at subject to inherent biases. Furthermore, this analysis did not an approximately 22% discount while charging payers the full 1,2 incorporate VTE events, so it is unknown whether 1 specific price. The program was designed to support hospitals car- VTE prophylaxis strategy was superior to another. ing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Reforming the 340B Drug Pricing Program

JAMA Internal Medicine , Volume 178 (8) – Aug 21, 2018

Loading next page...
 
/lp/american-medical-association/reforming-the-340b-drug-pricing-program-sZwStIbwHi

References (2)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2018.2007
Publisher site
See Article on Publisher Site

Abstract

Letters a background review for an American College of Physicians Clinical Practice cessful. However, most interventions have focused on Guideline. Ann Intern Med. 2011;155(9):602-615. increasing overall rates of prophylaxis rather than overall appropriateness. Although overall rates have improved, the 6. Rothberg MB. Venous thromboembolism prophylaxis for medical patients: who needs it? JAMA Intern Med. 2014;174(10):1585-1586. unintended consequence may be excess administration of VTE prophylaxis among low-risk patients. The major drawback to pharmacologic overprophylaxis is HEALTH CARE POLICY AND LAW major bleeding. Patient discomfort, potential risk of falls and Diversity of Participants in the 340B Drug Pricing impaired mobility with mechanical prophylaxis, medication Program for US Hospitals cost, and risk for heparin-induced thrombocytopenia are ad- The 340B program was initiated in 1992 by the US Congress ditional concerns. to allow participating hospitals to generate additional rev- Limitations of this study include its observational design enue by purchasing certain drugs used for outpatient care at subject to inherent biases. Furthermore, this analysis did not an approximately 22% discount while charging payers the full 1,2 incorporate VTE events, so it is unknown whether 1 specific price. The program was designed to support hospitals car- VTE prophylaxis strategy was superior to another. ing

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Aug 21, 2018

There are no references for this article.